ASLAN Pharmaceuticals

  • Pipeline
  • Our Team
  • Investor Relations
  • News & Publications
  • Contact
You are now leaving our web site.

The Website may contain links to or from other websites, over which ASLAN has no control. These linked sites are for your convenience only and you access them at your own risk.

ASLAN is not responsible for the content of the linked sites. ASLAN does not in any way endorse the linked sites.

I understand

Poster presented at ASH 2018: Preliminary Results of a Phase 2a Dose Optimization Study of ASLAN003 (DHODH inhibitor) in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible for Standard Therapy; Early Signs of Activity

Company

  • Our Pipeline
  • Our Team
  • Investor Relations
  • News & Publications
  • Contact
  • Terms and Conditions
 
Disclaimer

Copies of this poster obtained through QR codes are for personal use only and may not be reproduced without written permission of the authors

Accept
Decline
Decline